From: Antiplatelet and anticoagulant therapy in elective percutaneous coronary intervention
Reference | Drug (mg/day) | End points | Complications (%) |
---|---|---|---|
White et al [32] (n = 333) | 650 mg ASA and 225 mg | AMI and/or CABG | 5* versus 2* versus 14 |
 | dipyridamole, or 750 mg ticlopidine, |  |  |
 | or placebo |  |  |
Schwartz et al [33] (n = 376) | 330 mg ASA and 225 mg | Q-wave AMI | 1.6* versus 6.9 |
 | dipyridamole, or placebo |  |  |
Chesebro et al [34] (n = 207) | 975 mg ASA and 225 mg | Occlusion, AMI, urgent | 11 versus 20 |
 | dipyridamole, or placebo | reintervention |  |